KRAS mutation as a biomarker for survival in patients with non-small cell lung cancer, A meta-analysis of 12 randomized trials

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 10, 2015, Pages 4439-4445

  Ying, Min ^a   Zhu, Xiao Xia ^a   Zhao, Yang ^a   Li, Dian He ^a   Chen, Long Hua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

KRAS; Meta analysis; Non small cell lung cancer; Survival

Indexed keywords

KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; HUMAN; LUNG NEOPLASMS; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84930733078     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.10.4439     Document Type: Article

References (35)

1. Alimujiang S, Zhang T, Han Z-G, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-9.
2. Brugger W, Triller N, Blasinska-Morawiec M, et al (2011). Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol, 29, 4113-20.
3. Carney DN (2002). Lung Cancer-time to move on from chemotherapy. N Engl J Med, 346, 126-8.
4. Chetty R,Govender D (2013). Gene of the month: KRAS. J Clin Pathol, 66, 548-50.
5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
6. Douillard JY, Shepherd FA, Hirsh V, et al (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 28, 744-52.
7. Eberhard DA, Johnson BE, Amler LC, et al (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23, 5900-9.
8. Goss GD, O'Callaghan C, Lorimer I, et al (2013). Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol, 31, 3320-6.
9. Graziano SL, Gamble GP, Newman NB, et al (1999). Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol, 17, 668-75.
10. Herbst RS, Kelly K, Chansky K, et al (2010). Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advancedstage non-small-cell lung cancer: Southwest oncology group study S0342. J Clin Oncol, 28, 4747-54.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
12. Huncharek M, Muscat J,Geschwind JF (1999). K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis, 20, 1507-10.
13. Johnson ML, Sima CS, Chaft J, et al (2013). Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer, 119, 356-62.
14. Khambata-Ford S, Harbison CT, Hart LL, et al (2010). Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 28, 918-27.
15. Liberati A, Altman DG, Tetzlaff J, et al (2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med, 151, 65-94.
16. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective. J Natl Cancer Inst, 22, 719-48.
17. Martin P, Leighl NB, Tsao MS, Shepherd FA (2013). KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol, 8, 530-42.
18. Mascaux C, Iannino N, Martin B, et al (2005). The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 92, 131-9.
19. Meng D, Yuan M, Li X, et al (2013). Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer, 81, 1-10.
20. NCCN (2012). Clinical practice guidelines in oncology (NCCN Guidelines®): non-small cell lung cancer. Cochrane Database of Systematic Reviews 2014.
21. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol, 13, 795-805.
22. Pirker R (2013). EGFR-directed monoclonal antibodies in non-small cell lung cancer. Target Oncol, 8, 47-53.
23. Qi W-X, Shen Z, Lin F, et al (2012). Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82.
24. Ramalingam SS, Owonikoko TK, Khuri FR (2011). Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin, 61, 91-112.
25. Riely GJ, Kris MG, Rosenbaum D, et al (2008). Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res, 14, 5731-4.
26. Roberts PJ, Stinchcombe TE (2014). KRAS mutation: should we test for it, and does it matter? J Clin Oncol, 31, 1112-57.
27. Santos E, Martin-Zanca D, Reddy EP, et al (1984). Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science, 223, 661-4.
28. Schiller JH, Adak S, Feins RH, et al (2001). Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol, 19, 448-57.
29. Schiller JH, Gandara DR, Goss GD,Vokes EE (2013). Non-small-cell lung cancer: then and now. J Clin Oncol, 31, 981-3.
30. Shepherd FA, Domerg C, Hainaut P, et al (2013). Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol, 31, 2173-81.
31. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
32. Slebos RJ, Kibbelaar RE, Dalesio O, et al (1990). K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med, 323, 561-5.
33. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
34. Usuda K, Sagawa M, Motono N, et al (2014). Relationships between EGFR Mutation status of lung cancer and preoperative factors-are they predictive? Asian Pac J Cancer Prev, 15, 657-62.
35. Zhu CQ, da Cunha Santos G, Ding K, et al (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of canada clinical trials group study BR.21. J Clin Oncol, 26, 4268-75.